论文部分内容阅读
Chronic hepatits B (CHB) is an increasingly disturbing pub- lic health issue worldwide. Currently, interferon and oral antivi- ral drugs such as entecavir (ETV) or tenofovir disoproxil fumarate (TDF) are two intationally recognized drugs for the treatment of CHB. However, the HBeAg clearance or seroconversion rate is low even in patients with long-term antiviral therapy. Many patients have to increase the dosage of antiviral therapy drugs [1] . Intesti- nal microorganisms are confirmed to play an important role in the pathogenesis of different chronic liver diseases including CHB, and fecal microbiota transplantation (FMT) may be a novel treatment strategy for CHB.